Recombinant
RabMAb

Anti-CD31 (phospho Y713) antibody [EPR8079(2)] - C-terminal (ab180175)

Overview

  • Product name
    Anti-CD31 (phospho Y713) antibody [EPR8079(2)] - C-terminal
    See all CD31 primary antibodies
  • Description
    Rabbit monoclonal [EPR8079(2)] to CD31 (phospho Y713) - C-terminal
  • Host species
    Rabbit
  • Specificity
    ab180175 recognizes only the Y713-Phosphorylated form of Human CD31.
  • Tested applications
    Suitable for: WB, Flow Cyt, ICC/IFmore details
    Unsuitable for: IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human CD31 aa 700 to the C-terminus (C terminal) (phospho Y713) (Cysteine residue). The exact sequence is proprietary.
    Database link: P16284

  • Positive control
    • Pervanadate-treated Jurkat cells and lysate.
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Associated products

Applications

Our Abpromise guarantee covers the use of ab180175 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 82 kDa.
Flow Cyt 1/10 - 1/100.

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

ICC/IF 1/50 - 1/100.
  • Application notes
    Is unsuitable for IHC-P or IP.
  • Target

    • Function
      Induces susceptibility to atherosclerosis (By similarity). Cell adhesion molecule which is required for leukocyte transendothelial migration (TEM) under most inflammatory conditions. Tyr-690 plays a critical role in TEM and is required for efficient trafficking of PECAM1 to and from the lateral border recycling compartment (LBRC) and is also essential for the LBRC membrane to be targeted around migrating leukocytes. Prevents phagocyte ingestion of closely apposed viable cells by transmitting 'detachment' signals, and changes function on apoptosis, promoting tethering of dying cells to phagocytes (the encounter of a viable cell with a phagocyte via the homophilic interaction of PECAM1 on both cell surfaces leads to the viable cell's active repulsion from the phagocyte. During apoptosis, the inside-out signaling of PECAM1 is somehow disabled so that the apoptotic cell does not actively reject the phagocyte anymore. The lack of this repulsion signal together with the interaction of the eat-me signals and their respective receptors causes the attachment of the apoptotic cell to the phagocyte, thus triggering the process of engulfment). Isoform Delta15 is unable to protect against apoptosis. Modulates BDKRB2 activation. Regulates bradykinin- and hyperosmotic shock-induced ERK1/2 activation in human umbilical cord vein cells (HUVEC).
    • Tissue specificity
      Expressed on platelets and leukocytes and is primarily concentrated at the borders between endothelial cells. Isoform Long predominates in all tissues examined. Isoform Delta12 is detected only in trachea. Isoform Delta14-15 is only detected in lung. Isoform Delta14 is detected in all tissues examined with the strongest expression in heart. Isoform Delta15 is expressed in brain, testis, ovary, cell surface of platelets, human umbilical vein endothelial cells (HUVECs), Jurkat T-cell leukemia, human erythroleukemia (HEL) and U937 histiocytic lymphoma cell lines (at protein level).
    • Sequence similarities
      Contains 6 Ig-like C2-type (immunoglobulin-like) domains.
    • Domain
      The Ig-like C2-type domains 2 and 3 contribute to formation of the complex with BDKRB2 and in regulation of its activity.
    • Post-translational
      modifications
      Phosphorylated on Ser and Tyr residues after cellular activation. In endothelial cells Fyn mediates mechanical-force (stretch or pull) induced tyrosine phosphorylation.
    • Cellular localization
      Membrane. Cell junction. Localizes to the lateral border recycling compartment (LBRC) and recycles from the LBRC to the junction in resting endothelial cells and Cell junction. Localizes to the lateral border recycling compartment (LBRC) and recycles from the LBRC to the junction in resting endothelial cells.
    • Information by UniProt
    • Database links
    • Alternative names
      • Adhesion molecule antibody
      • CD31 antibody
      • CD31 antigen antibody
      • CD31 EndoCAM antibody
      • EndoCAM antibody
      • FLJ34100 antibody
      • FLJ58394 antibody
      • GPIIA antibody
      • GPIIA' antibody
      • PECA1 antibody
      • PECA1_HUMAN antibody
      • Pecam 1 antibody
      • PECAM 1 CD31 EndoCAM antibody
      • PECAM antibody
      • PECAM-1 antibody
      • Pecam1 antibody
      • Platelet and endothelial cell adhesion molecule 1 antibody
      • Platelet endothelial cell adhesion molecule antibody
      • Platelet/endothelial cell adhesion molecule 1 antibody
      see all

    Images

    • Flow cytometric analysis of permeabilized, Pervanadate-treated Jurkat cells labeling CD31 (Phospho Y713) using ab180175 at 1/10 (red) or a rabbit IgG negative (green).

    • All lanes : Anti-CD31 (phospho Y713) antibody [EPR8079(2)] - C-terminal (ab180175) at 1/1000 dilution

      Lane 1 : Non-treated Jurkat cell lysate
      Lane 2 : Pervanadate-treated Jurkat cell lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Standard HRP goat anti-rabbit at 1/2000 dilution

      Developed using the ECL technique.

      Predicted band size: 82 kDa

    • Dot blot analysis of CD31 (pY713) peptide (Lane 1) and CD31 non-phospho peptide (Lane 2) labelling CD31 (phospho Y713) with ab180175 at a dilution of 1/1000. A Peroxidase-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody at a dilution of 1/2500.

      Blocking and dilution buffer: 5% NFDM/TBST.

      Exposure time: 10 seconds.

    References

    This product has been referenced in:
    • DU H  et al. Cross-talk between endothelial and tumor cells via basic fibroblast growth factor and vascular endothelial growth factor signaling promotes lung cancer growth and angiogenesis. Oncol Lett 9:1089-1094 (2015). IF . Read more (PubMed: 25663861) »

    See 1 Publication for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab180175.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up